Discover how TTR
destabilization is the
source of ATTR-CM.1,2
Examine strategies for clinical care.
ATTR-CM is also known as ATTR cardiomyopathy,
or
ATTR cardiac amyloidosis (ATTR-CA).
Every Moment Matters
Patients can't wait and neither should you.
Select a topic below:
Why TTR Matters
Discover the essential role of TTR in the body.
Recognizing ATTR-CM
See red flags for identifying patients with ATTR-CM.
Diagnosing ATTR-CM
Explore the ATTR-CM diagnostic algorithm and patient profiles.
Managing ATTR-CM
Learn about the latest management strategies.
ATTR-CM=transthyretin amyloid cardiomyopathy; TTR=transthyretin.
Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-e22. 2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. 3. Morfino P, Aimo A, Vergaro G, et al. Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy. Pharmaceutics. 2023;15(4):1129.
For US Healthcare Professionals
The information provided on this site is intended for use by healthcare professionals practicing in the United States.
By clicking Continue, you confirm you are a healthcare professional practicing in the United States.
Thank you for visiting
TTRMatters.com
If you are a healthcare provider and want to learn more about an ATTR-CM treatment option, click Continue.
To remain on TTRMatters.com, click Stay.
Thank you for visiting TTRMatters.com
You are about to leave TTRMatters.com and visit an external site. BridgeBio is not responsible for the content and privacy practices of the site you're about to redirect to.